Regeneron Pharmaceuticals shares have dipped 3% since the U.S. Department of Justice filed a complaint accusing the company ...

On Wednesday, TD Cowen showed confidence in Regeneron Pharmaceuticals Inc (NASDAQ:REGN), adjusting the stock's price target to $1,030 from $1,020, while reiterating a Buy rating. The revision ...

$907.32 15.17% Truist Securities ...

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Regeneron (REGN), which belongs to the Zacks ...

It was a busy week in the biotech sector with lots of important regulatory and pipeline updates. Among these, biotech giant Regeneron REGN was in the news on a complaint alleging fraudulent drug ...

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the ...

Today's Research Daily features new research reports on 16 major stocks, including Danaher Corp. (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW). These research ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “These latest clinical results build on our ongoing commitment to cancer research and reflect our focus ...